// App-Quantinova.ai

2169 : Symptom Burden and Quality of Life in High-Risk Essential Thrombocythemia and Polycythemia Vera Patients Receiving Hydroxyurea or Pegylated Interferon Alfa-2a: Results of Myeloproliferative Neoplasms Research Consortium (MPN-RC) 111 and 112 Trials

Researchers

Presenter

  • Gina L. Mazza

Principal Investigators

  • Carolyn Mead-Harvey

  • John Mascarenhas

  • Abdulraheem Yacoub

  • Ronald Hoffman

  • Heidi E. Kosiorek

  • Josef T. Prchal

  • Richard T. Silver

  • Tiziano Barbui

  • Amylou C. Dueck

  • Ruben Mesa

Medical Centers

  • Department of Health Sciences Research, Mayo Clinic, Rochester, MN

  • The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

  • University of Kansas Medical Center, Westwood, KS

  • Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT

  • Weill Cornell Medical College, New York, NY

  • Ospedali Riuniti, Bergamo, Italy

  • Mays Cancer Center, UT Health San Antonio, San Antonio, TX, USA

Locations

  • United States

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Myeloid neoplasms

  • Essential thrombocythemia

  • Polycythemia vera

  • Venous thrombosis

Biomarkers

  • Interferon

Drug/Treatment

  • interferon alfa-2a

  • Hydroxyurea

  • Hydroxycarbamide

  • Interferon

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT01259817

  • NCT01258856

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved